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Abstract  
Background: Atrial fibrillation (AF) is highly prevalent in older persons and is associated with considerable morbidity and mortality. 
Assessing appropriateness of drug therapy in AF may be facilitated by application of medication assessment tools (MATs).  
Objective: To develop, psychometrically evaluate and apply an innovative MAT for the long-term management of AF with particular 
relevance to older persons.  
Methods: Key recommendations from clinical practice guidelines for the long-term management of AF were selected and review 
criteria defining appropriate drug therapy were constructed as a ‘qualifying statement’ followed by a ‘standard’. The developed MAT 
was given the designation MAT-AF. An application guide was compiled where justifications for non-adherence were specified. Content 
validity was tested by an expert group using a three-round Delphi process. Inter- and intra-observer reliability testing was conducted 
with agreement expressed by Cohen’s kappa and application time measured to assess feasibility. MAT-AF was applied to 150 patients 
with a diagnosis of AF admitted to a rehabilitation hospital.  
Results: MAT-AF consists of 15 criteria sectioned into antithrombotic, rate control and rhythm control therapy. Content validity was 
demonstrated for all criteria. Reliability was confirmed with kappa values of 0.84 and 0.91 for inter- and intra-observer agreements. 
Mean application time for the two observers was 3.9 and 2.4 minutes, which decreased significantly in the second application 
conducted after a four-week interval (p<0.001).  Overall adherence to applicable criteria was 59.8%. Non-adherence was evident for 
prescription of anticoagulation in patients with a CHA2DS2VASc score ≥1 (29.5%). Monitoring of laboratory parameters for digoxin was 
suboptimal. Ophthalmic and pulmonary monitoring and patient counselling regarding amiodarone therapy could not be assessed since 
relevant records were not readily available.  
Conclusion: MAT-AF application highlighted key aspects which need to be addressed to improve patient care. 
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INTRODUCTION 
Atrial fibrillation (AF) is considered to be one of the major 
causes of stroke and heart failure.1 In a systematic review, 
Chugh et al. reported a progressive increase in global 
prevalence of AF with higher rates observed in the older 
age groups.2 Management recommendations focus on 
reducing thromboembolic risk and on rate and rhythm 
control.1,3-5 Although recent data shows good progress in 
the management of patients with AF, there is still 
substantial evidence of suboptimal therapy.6-9  
A number of drug utilisation review tools have been 
developed for the purpose of identifying potentially 
inappropriate drug therapy, predominantly targeting the 
older population from a generic perspective rather than for 
specific disease states.10,11 Only some aspects of AF 
management have been incorporated in these tools, the 
most commonly cited being the Beers’ Criteria12, the 
Screening Tool of Older Persons’ Prescriptions (STOPP) and 
the Screening Tool to Alert Doctors to Right Treatment 
(START).13 Medication assessment tools (MATs) are 
disease-specific, evidence-based instruments designed to 
assess appropriateness of drug therapy and have been 
developed and applied in various diseases including heart 
failure, diabetes mellitus, coronary heart disease, cancer 
pain, asthma, pneumonia and rheumatoid arthritis.14-21 A 
MAT that is specific for AF, taking into consideration 
different management strategies, concurrent multiple 
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morbidities and monitoring for safe use of therapeutic 
agents, provides an assessment of appropriateness of drug 
therapy for this disease state. 
The aim of the study was to design, psychometrically 
evaluate and apply an innovative MAT for the long-term 
management of AF, with particular relevance to older 
persons, so as to assess adherence to guideline 
recommendations. 
 
METHODS 
MAT design and validation 
The MAT was designed by the researcher (MG) according to 
the most recent evidence-based guidelines for the long-
term management of AF.1,3-5 Additional information 
relating to therapeutic agents was obtained from drug 
monographs. Review criteria defining appropriate drug 
therapy were constructed as a ‘qualifying statement’ 
followed by a ‘standard’, based on the format of previously 
published MATs.14-21 For example, ‘patient with atrial 
fibrillation who has a CHA2DS2VASc score of ≥1 (≥2 if 
female)’ is the qualifying statement and ‘is prescribed 
warfarin (INR 2.0-3.0) or other oral anticoagulant’ is the 
standard. Response options include ‘not applicable’ when 
the criterion is not applicable, ‘yes’ for adherence, ‘no’ for 
non-adherence and ‘justified no’ when there is a justified 
reason for non-adherence to the standard. When data is 
insufficient to apply the criterion or to assess if the 
standard is achieved, the response options are ‘insufficient 
data relating to qualifying statement’ or ‘insufficient data 
relating to standard’. The developed MAT was given the 
designation MAT-AF. An application guide incorporating 
instructions for response options for each criterion was 
compiled.  
Content validation of MAT-AF was undertaken by an expert 
group composed of three consultant cardiologists, three 
consultant geriatricians and three clinical pharmacists 
practising in geriatrics using a three-round Delphi 
technique. Consensus threshold was set to ≥75%.16,19,20 The 
application guide was reviewed based on 
recommendations by the expert group. The final version of 
MAT-AF consisted of a one-page paper-based tool. 
Reliability and feasibility testing  
Reliability and feasibility testing was conducted during a 
pilot study in which MAT-AF was applied by the researcher 
(MG) to a sample of 30 patients admitted to a 
rehabilitation hospital. Inclusion criteria were a diagnosis of 
AF (reason for admission or past history) and age ≥60 years. 
Patients who were discharged to acute care or deceased 
during the study period were excluded. Information for 
MAT application was obtained from patient profiles 
compiled by clinical pharmacists in daily practice for each 
patient admitted to the hospital for the purpose of 
pharmaceutical care issue documentation.  
MAT-AF was tested by two pharmacists (observers) who 
each applied the review criteria to the 30 patient profiles. 
The observers were selected on the basis that they were 
familiar with the study setting and had a comparable level 
of experience in clinical pharmacy. The application guide 
was given to the observers to ensure consistency in 
application and interpretation of MAT-AF. Application of 
MAT-AF was repeated by the same observers for the same 
30 patient profiles after a period of four weeks. Reliability 
testing in terms of inter- and intra-observer agreement to 
the response option selected was calculated using Cohen’s 
kappa. Feasibility testing was performed using paired-
samples t-test to identify inter- and intra-observer 
differences in application time and correlation between the 
observers’ application time. 
Adherence to the compiled MAT 
Adherence to MAT-AF was assessed in a sample of 150 
patients admitted to the rehabilitation hospital with a 
diagnosis of AF. MAT-AF was applied by the researcher to 
patients identified consecutively at discharge during the 
period March to September 2016. Selection of patients and 
data extraction was according to the methodology adopted 
for reliability and feasibility testing. Clinical notes, 
laboratory results and discharge case summaries were used 
as necessary. Adherence to MAT criteria was calculated by 
the sum of the ‘yes’ responses expressed as a percentage 
of the applicable criteria. Criterion responses which were 
not applicable or which had insufficient data relating to the 
qualifying statement were not considered in the adherence 
calculation. 
 
RESULTS  
In the first round of the Delphi validation process, 
consensus was achieved for eight of the fifteen criteria in 
MAT-AF. Adjustments were made to five criteria, two 
criteria were removed and three new criteria were created. 
In the second validation round, consensus was obtained for 
Table 1. Patient characteristics for study population (n=150) 
Gender (n, %)*   
male 54 36.0% 
female 96 64.0% 
Age (years)   
mean (SD) 81.7 (7.6) 
min,  max 60 97 
≥75 years (n, %) 127 84.7% 
Atrial fibrillation (n, %)   
paroxysmal 54 36.0% 
persistent 12 8.0% 
permanent 84 56.0% 
Comorbidities (current or past history) (n, %)   
heart failure 93 62.0% 
hypertension 108 72.0% 
diabetes  48 32.0% 
stroke/TIA/systemic thromboembolism 51 34.0% 
vascular disease**  52 34.7% 
anaemia 68 45.3% 
chronic kidney disease (CrCl <60ml/min) 103 68.7% 
CHA2DS2VASc score (0-9)   
mean (SD) 5.0 (1.6) 
min,  max 0 9 
HAS-BLED score (0-9)   
mean (SD) 2.0 (0.8) 
min,  max 1 4 
*male to female ratio of study population reflects gender ratio of 
rehabilitation hospital  
**acute coronary syndrome or peripheral arterial disease 
(including revascularisation) 
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all sixteen criteria. A third round was necessary to review 
three criteria which were adjusted to reflect guideline 
updates regarding digoxin use following which consensus 
was achieved for two criteria and one criterion was 
removed. MAT-AF after validation was composed of fifteen 
review criteria sectioned into antithrombotic, rate control 
and rhythm control therapy. Details on criteria validation 
may be viewed in Table 1 of the supplementary material. 
Reliability testing resulted in kappa values of 0.84 (p<0.001) 
and 0.91 (p<0.001) for inter- and intra-observer 
agreements. Mean application time was 3.90 (SD=1.18) 
minutes for observer 1 and 2.38 (SD=0.95) minutes for 
observer 2. Following the four-week period, mean 
application time for observer 1 was 2.12 (SD=0.92) minutes 
and 1.56 (SD=0.41) minutes for observer 2, both 
significantly lower than the time for the first application 
(p<0.001). Correlations were significant for both inter-
observer (r=0.5, p=0.005) and intra-observer tests (r=0.7, 
p<0.001 and r=0.5, p=0.008). 
Patient characteristics and MAT-adherence results of the 
150 patients assessed during MAT-AF application are 
shown in Table 1 and Table 2, respectively. Adherence to 
the applicable criteria was 59.8% and justified non-
adherence was 11.1%. Non-adherence was evident for 
prescription of anticoagulation in patients with a 
CHA2DS2VASc score ≥1 (29.5%). Monitoring of laboratory 
parameters relating to digoxin therapy was deficient in 
49.1% of patients, predominantly due to absence of 
magnesium levels, and in 26.1% of patients at risk of high 
serum digoxin concentrations. Ophthalmic and pulmonary 
monitoring and patient counselling regarding amiodarone 
therapy could not be assessed as relevant records were not 
readily available. Cardiology referral was not performed in 
most of the patients for whom it was recommendable.  
 
DISCUSSION 
Reliability of MAT-AF was confirmed and was similar to 
other MATs.16,19,20  There was a significant correlation for 
the two observers in the time spent on MAT-AF application 
for the same patient case. Following the four-week interval, 
the application time for both observers was significantly 
lower compared to the first application, possibly indicating 
that repeated use of the MAT facilitates application. The 
Table 2. Adherence to applicable criteria of MAT-AF in 150 patients (n=458) 
 
Applicable  
cases 
Adherence 
Justified  
non-
adherence 
Non- 
adherence 
Insufficient 
data for 
standard 
Antithrombotic therapy n % n % 95%CI n % n % n % 
1 No antithrombotic therapy if CHA2DS2VASc score 0 1 0.7 1 100 - 0 0 0 0 0 0 
2 Oral anticoagulant if CHA2DS2VASc score ≥1 149 99.3 91 61.1 53.3:68.9 14 9.4 44 29.5 0 0 
3 
Recommended dose of direct anticoagulant if CrCl 
≥50 mL/min 
5 3.3 4 80.0 44.9:100 0 0 1 20.0 0 0 
4 
Direct oral anticoagulant at lower dose or warfarin if 
CrCl between 15 – 49 mL/min 
47 31.3 47 100 - 0 0 0 0 0 0 
5 Warfarin if CrCl <15 mL/min 1 0.7 1 100 - 0 0 0 0 0 0 
Rate control therapy            
6 
Beta-blocker, non-dihydropyridine calcium channel 
blocker or digoxin 
97 64.7 51 52.6 42.6:62.6 31 32.0 15 15.5 0 0 
7 
Cardiology referral/follow-up if non-dihydropyridine 
calcium channel blocker and contraindicated/not 
tolerated 
1 0.7 0 0 - 0 0 1 100.0 0 0 
8 
Beta-blocker or digoxin if heart failure with left 
ventricular ejection fraction <40% 
12 8.0 8 66.7 40.0:93.4 4 33.3 0 0 0 0 
9 
Monitoring of renal and thyroid function, serum 
electrolytes with digoxin and within range 
53 35.3 27 50.9 37.4:64.4 0 0 26 49.1 0 0 
10 
Monitoring of serum digoxin level if at risk of high 
serum concentration and within range 
23 15.3 17 73.9 55.9:91.9 0 0 6 26.1 0 0 
11 
Amiodarone for additional rate control or 
contraindication/intolerance to other agents 
1 0.7 0 0 - 0 0 1 100 0 0 
12a 
Monitoring of liver and thyroid function with 
amiodarone and within range 
21 14.0 17 81.0 64.1:97.9 0 0 4 19.0 0 0 
12b 
Monitoring of ophthalmic and pulmonary function, 
and counselling with amiodarone 
21 14.0 0 0 - 0 0 0 0 21 100.0 
Rhythm control therapy            
13 
Continuation at prescribed dose if maintained in 
sinus rhythm with antiarrhythmic agent and well 
tolerated 
10 6.7 7 70.0 41.6:98.4 0 0 3 30.0 0 0 
14 
Cardiology referral/follow-up if maintained in sinus 
rhythm with antiarrhythmic agent and 
contraindicated/not well tolerated 
3 2.0 0 0 - 0 0 3 100.0 0 0 
15 
Cardiology referral/follow-up if prescribed 
antiarrhythmic agent and not maintained in sinus 
rhythm 
13 8.7 3 23.1 0.2:46.0 2 15.4 8 61.5 0 0 
Total criteria 458 19.1 274 59.8 55.3:64.3 51 11.1 112 24.5 21 4.6 
‘applicable criteria’ exclude ‘not applicable’ and ‘insufficient data relating to qualifying statement’ response options.  CrCl: Creatinine clearance. 
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short application time supports application of MAT-AF in a 
clinical setting. 
Specific aspects that are applicable to a few patients were 
also included in the MAT resulting in a low applicability for 
these criteria when considering the entire patient cohort.  
The incorporation of such criteria is clinically relevant as 
otherwise important aspects may be overlooked.  
Application of MAT-AF indicated the need for increased 
prescribing of anticoagulation in the study population. 
Underutilisation of anticoagulation, particularly in the older 
population, has been reported in several studies.7-9 
Appropriate anticoagulation is particularly important 
among older persons since this patient group is at greater 
risk of stroke attributable to AF.22 Recurrent falls or a high 
risk for falls was a common reason for withholding 
anticoagulation therapy in the study population as has 
been reported in other studies.8,23,24 Although AF guidelines 
caution the use of anticoagulation therapy in patients at 
risk for falls, recommendations specify that these agents 
should only be withheld in patients with severe 
uncontrolled falls such as epilepsy or advanced multisystem 
atrophy with backward falls.1  
Monitoring of laboratory and other parameters is 
recommended to reduce complications of AF therapy.1 
Chronic kidney disease, other comorbidities and multiple 
medication increase the risk of adverse drug reactions in 
this patient group. MAT-AF application highlighted 
deficiencies in the monitoring required with digoxin 
therapy, predominantly regarding serum magnesium and 
digoxin levels in patients at risk of toxicity. Shortcomings 
were also evident in assessing whether the required 
monitoring with amiodarone was conducted. 
Guidelines for the management of AF emphasize that 
patients on antiarrhythmic agents should be periodically 
evaluated to confirm appropriateness of treatment.1 Drug 
therapy which was favourable when initially prescribed 
may not remain effective in maintaining sinus rhythm or 
may become inappropriate once the patient develops 
additional comorbidities. During MAT-AF development, 
cardiology referral was considered recommendable in 
these patients. In this study there was a tendency for 
treatment decisions to be taken without cardiology 
referral, predominantly resulting in patients being retained 
on antiarrhythmic agents despite sinus rhythm not being 
maintained. 
The application of MAT-AF has led to identification of areas 
for improvement in terms of prescribing of anti-
thrombotics, monitoring parameters to ensure drug safety 
and identification of patients warranting referral. MAT-AF 
additionally provides a means for individual patient 
assessment by the clinical team to identify patient-specific 
therapy needs. In a follow-up study, MAT-AF is being 
implemented by clinical pharmacists at the rehabilitation 
hospital to assess whether application of the tool in daily 
practice enhances optimisation of treatment. 
 
CONCLUSIONS 
MAT-AF application highlighted key aspects which need to 
be addressed. The application of such tools in clinical 
practice can support the challenging task of optimising drug 
therapy in older persons.  
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